Overview

Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930

Status:
Not yet recruiting
Trial end date:
2022-07-18
Target enrollment:
Participant gender:
Summary
This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical